Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Julphar
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
McKinsey
QuintilesIMS
Cerilliant
Queensland Health

Generated: May 26, 2018

DrugPatentWatch Database Preview

VELOSEF Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Velosef patents expire, and when can generic versions of Velosef launch?

Velosef is a drug marketed by Apothecon, Bristol Myers Squibb, and Ersana. and is included in five NDAs.

The generic ingredient in VELOSEF is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
Summary for VELOSEF
Drug patent expirations by year for VELOSEF
Medical Subject Heading (MeSH) Categories for VELOSEF
Synonyms for VELOSEF
(6R- -( -3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid
(6R,7R)-7-((R)-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
(6R,7R)-7-[(2R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-yl-acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
38821-53-3
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methyl-8-oxo-, (6R-(6-alpha,7-beta(R*)))-
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino-1,4-cyclohexadien-1-ylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-
5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[(2R)-2-amino-2-(1,4-cyclohexadien-1-yl)acetyl]amino]-3-methyl-8-oxo-,(6R,7R)-
58456-86-3 (dihydrate)
7-(D-2-Amino-2-(1,4-cyclohexadien-1-yl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)-oct-2-ene-2-caboxylic acid
7-(D-2-Amino-2-(1,4-cyclohexadienyl)acetamide)desacetoxycephalosporanicacid
7beta-[(2R)-2-(cyclohexa-1,4-dienyl)-2-phenylacetamido]-3-methyl-3,4-didehydrocepham-4-carboxylic acid
821C533
9YA6SX5S4D
AC-1409
AC1L1Z38
AC1Q6LOA
AKOS015961130
AN-14970
Anspor
Anspor (TN)
API0001934
BC205857
BCP9000506
BCPP000291
BDBM50370585
BRN 6075388
C06897
CAS-38821-53-3
CCG-208520
CED
cefradex
Cefradin
Cefradina
Cefradina [INN-Spanish]
Cefradine
Cefradine (JAN/INN)
Cefradine [INN]
Cefradine for peak identification, European Pharmacopoeia (EP) Reference Standard
Cefradine, European Pharmacopoeia (EP) Reference Standard
Cefradinum
Cefradinum [INN-Latin]
Cekodin
Cephradin
cephradine
Cephradine (anhydrous)
Cephradine (USP)
Cephradine [USAN:BAN]
CEPHRADINE SODIUM
CHEBI:3547
CHEMBL1604
CS-4608
D00264
D06KKS
DB01333
DivK1c_000739
DSSTox_CID_2785
DSSTox_GSID_22785
DSSTox_RID_76729
DTXSID4022785
EINECS 254-137-8
Epitope ID:116210
Eskacef
FT-0603004
GTPL4830
HE340268
HMS502E21
HSDB 3216
HY-B1156
IDI1_000739
Infexin
KB-62948
KBio1_000739
LS-149955
Megace f
Megacef
MFCD00865048
MolPort-003-940-846
NCGC00183036-01
NCGC00183036-02
NCGC00263658-01
NINDS_000739
RDLPVSKMFDYCOR-UEKVPHQBSA-N
s4671
SC-13473
SCHEMBL3244
Sefril
SK-D-39304
SK&F D-39304
SK&F-D39304
SKF D 39304
SQ 11436
SQ-11436
SQ-22022
SQ-22022 [Dihydrate]
Tox21_113488
Tox21_113488_1
UNII-9YA6SX5S4D
Velocef
VELOSEF '125'
VELOSEF '250'
VELOSEF '500'
Velosef (TN)
VELOSEF 125
VELOSEF 250
VELOSEF 500
ZINC3830515

US Patents and Regulatory Information for VELOSEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apothecon VELOSEF cephradine CAPSULE;ORAL 061764-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apothecon VELOSEF cephradine INJECTABLE;INJECTION 061976-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Apothecon VELOSEF cephradine INJECTABLE;INJECTION 061976-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ersana VELOSEF '500' cephradine CAPSULE;ORAL 050548-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Deloitte
Fish and Richardson
US Department of Justice
AstraZeneca
Cipla
Cantor Fitzgerald
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.